GU Cancers 2025 | What remaining unmet needs are there in oligometastatic prostate cancer?

Alexander Sherry • 13 Feb 2025

GU Cancers 2025

Alexander Sherry, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the unmet needs in oligometastatic prostate cancer, highlighting the need for more translational work to identify patients most likely to benefit from specific therapies and to balance disease control with quality of life. Dr Sherry emphasizes the importance of refining the definition of oligometastatic disease, including the use of modern imaging modalities and novel biomarkers, to better tailor treatment strategies. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.